Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE: PFE) Xtandi quickly gained ground on Johnson & Johnson's (NYSE: JNJ) multibillion-dollar Zytiga. However, Xtandi's momentum has slowed, leaving some to question if Pfizer's $14 billion acquisition of Medivation to land Xtandi was a mistake.
This week, Pfizer may have alleviated some of that concern by reporting new data from a trial showing Xtandi delays the spread of this cancer in non-metastatic patients.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Johnson & Johnson Aktie
149,04 €
0,20 %
Klare Kaufstimmung für Johnson & Johnson: Viel mehr Buy- als Sell-Einschätzungen.
Das Community-Kursziel von 194 € für Johnson & Johnson deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 149.04 € hin.
